In a multidisciplinary effort, combining different analyses in multiple cancer models and types, we demonstrate that SLFN11 represents an important biomarker for the stratification of DDA therapies, but not to DDRi monotherapies in breast cancer. Here, SLFN11 is linked to breast carcinoma.